While pharmaceuticals have so far been spared from import taxes, Trump has vowed to impose a “major” tariff on the sector “very shortly.” He has suggested levies might be as high as 200%—part of his ...

ToolGen commences legal action in UK court over Vertex's genome editing therapy, CASGEVY ®Seeks to expand licensing of its proprietary CRISPR RNP technologySEOUL, South Korea, April 21, 2025 /PRNewswi ...

CASGEVY became the world's first genome editing therapy to receive marketing authorization, beginning with the United Kingdom ...

A federal district court had ruled in favor of HHS, restricting Vertex's ability to provide fertility preservation services to Medicaid patients.

Equity markets have been seesawing for the past two weeks. Stocks fell hard after President Donald Trump announced his tariff ...

Kewalramani becme the first female CEO of a large, public U.S. biotechnology company after immigrating from India at age 11 ...

Reshma Kewalramani, CEO of Vertex Pharmaceuticals, is honored as one of Time's 100 most influential people of 2025. Under her ...

TIME magazine has released the list of the 100 Most Influential People of 2025 and Reshma Kewalramani, Indian-origin CEO, is ...

Under Reshma Kewalramani's leadership, Vertex achieved a major milestone with the FDA’s first-ever approval of a CRISPR-based ...

Indian American physician-scientist and business executive Reshma Kewalramani, the CEO of Vertex Pharmaceuticals, has been ...

Born in Mumbai, Reshma moved to the United States in 1988. She pursued a career in medicine, earning her degree from Boston ...

Trained in internal medicine and nephrology, Reshma once intended to teach, treat patients, and work in a lab after medical ...